• Omar S Khokhar, Arash Farhadi, Lisa McGrail, and James H Lewis.
• Department of Medicine, Division of Gastroenterology, Hepatology Section, Georgetown University Hospital, Washington, DC, USA. okhokhar78@yahoo.com
• Chemotherapy. 2009 Jan 1; 55 (2): 69-75.

Background/AimsThe risk of chronic hepatitis B virus reactivation under the influence of chemotherapy or immunosuppression is being increasingly recognized. However, many oncologists either have not observed this complication or are not aware of current recommendations for hepatitis B prophylaxis. Our aims were to determine the awareness of the reactivation risk and to understand the screening and prevention practices among oncologists.MethodsA questionnaire survey was administered to oncologists in the Washington, D.C., area.ResultsResponses from 131 practitioners to the 10 questions were received. Nearly 80% of respondents were aware of reactivation, but only 30% had seen a case and only 56% were aware of prophylactic therapy. Fourteen percent of oncologists screened all patients, whereas 86% screened selectively based on risk factors. Most (76%) would use prophylaxis in a patient with active hepatitis B virus, but only about half would treat chronic carriers or those with resolved infection. Regarding choice of prophylaxis, nearly half (48%) were unsure of which agent to use.ConclusionsImproving awareness of hepatitis B virus reactivation and antiviral prophylaxis in the oncology community seems warranted.Copyright 2008 S. Karger AG, Basel.

13 keywords...

hide…